ClinicalTrials.gg
CompletedNCT00157053Updated Aug 24, 2021

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

A Phase 2/3 interventional study of Antihemophilic factor, recombinant, manufactured protein-free in Hemophilia A, sponsored by Baxalta now part of Shire. Completed at 24 sites in 9 countries. Open to male participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2021-08-24.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 9 months after the study started (first participant enrolled Nov 2001, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
82
Allocation
Non-randomized
Ages
10 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.

Enrollment
3rd of 21
82 · median 50
Started
2001
with 1 other
Phase 2/3
3 of 21
none open now
Registered
1st of 21
by date
Lead sponsor
8 of 21
Baxalta now part of Shire

Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 3rd largest by enrollment, is one of 2 that started in 2001, is one of 3 in phase 2/3, and was the 1st registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About antihemophilic factor, human recombinant

antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 10 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of hemophilia A subjects. The study consists of 2 parts: Part 1 is a pharmacokinetic and safety study, and Part 2 is an evaluation of efficacy and safety. The study is open to patients who completed Baxter Study 069901.

03

Conditions studied

  • Hemophilia A

Browse trials for

Keywords

  • Factor VIII Deficiency
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has completed Baxter protocol 069901
  • Subject is -1 seronegative or, if HIV-1 seropositive, has a >= 400/mm3 documented within three months of the screening visit
  • Subject (and his legally acceptable representative, in the case of study participants >= 10 and \< 18 years of age) has been informed of the nature of the study, agreed to its provisions, and signed and dated the form approved by the appropriate IRB/IEC and Baxter

Exclusion criteria

Exclusion Criteria:

  • The subject received factor VIII products other than rAHF-PFM upon completion of Baxter protocol 069901
  • The subject developed an inhibitor to factor VIII, measured in the central laboratory, during Baxter protocol 069901. An inhibitor is defined as a Bethesda titer > 1.0 or, if Bethesda titer \< 1.0, confirmation using the Nijmegen modification of the Bethesda assay with a titer > 0.6
  • The subject is scheduled to receive an immunomodulating drug other than anti-retroviral chemotherapy (e.g., a-interferon, ) during the course of the study
  • The subject is identified by the investigator as being unable or unwilling to cooperate with study procedures
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Terminal phase half-life for Recombinant Antihemophilic Factor (rAHF-PFM)

    Time frame: Within 30 minutes prior to the pharmacokinetic infusion and at 1 hour ± 5 minutes, 9 ± 1 hour, 24 ± 2 hours, and 48 ± 2 hours after the infusion.

07

Study locations

24 sites
  • Mountain States Regional Hemophilia and Thrombosis Center
    Aurora, Colorado 80045, United States
  • Childrens Healthcare of Atlanta Blood Bank
    Atlanta, Georgia 30322, United States
  • Comprehensive Bleeding Disorders Center
    Peoria, Illinois 61614, United States
  • Indiana Hemophilia & Thrombosis Center
    Indianapolis, Indiana 46260, United States
  • Michigan State University
    East Lansing, Michigan 48824, United States
  • University of Medicine & Dentistry of New Jersey
    New Brunswick, New Jersey 08903-0019, United States
  • Cornell Medical Center
    New York, New York 10021, United States
  • Mt. Sinai Medical School
    New York, New York 10029, United States
  • Children's Hospital Medical Center Pharmacy
    Cincinnati, Ohio 45229, United States
  • Hemophilia Center of Western Pennsylvania
    Pittsburgh, Pennsylvania 15213-4306, United States
  • Puget Sound Blood Center
    Seattle, Washington 98104-1256, United States
  • Allgemeines Krankenhaus der Stadt Wien
    Vienna, 1090, Austria
  • KU Leuven Universitaire Ziekenhuizen
    Leuven, 3000, Belgium
  • University of Alberta
    Calgary, Alberta 470 MSB, Canada
  • Hôpital Edouard Herriot
    Lyon, 69437, France
  • Klinikum der J. W. Goethe - Universität
    Frankfurt am Main, 60590, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30623, Germany
  • Klinikum Innenstadt der Universität München
    Munich, D-80336, Germany
  • Ospedale Maggiore di Milano
    Milan, 20122, Italy
  • University Hospital MAS
    Malmö, S-20502, Sweden
  • The Royal Free Hospital
    London, England NW3 2QG, United Kingdom
  • Central Manchester Healthcare NHS Trust
    Manchester, England M13 9WL, United Kingdom
  • The Churchill Hospital
    Oxford, England OX3 7LJ, United Kingdom
  • University Hospital of Wales
    Cardiff, Wales CF4 4XW, United Kingdom
08

References and documents

Publications

  • Shapiro A, Gruppo R, Pabinger I, Collins PW, Hay CR, Schroth P, Casey K, Patrone L, Ehrlich H, Ewenstein BM. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opin Biol Ther. 2009 Mar;9(3):273-83. doi: 10.1517/14712590902729392. PubMed 19216617 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2001 to primary completion in Aug 2004, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
StartActual
Nov 22, 2001
Primary completionActual
Aug 3, 2004
CompletionActual
Aug 3, 2004
Last update
Aug 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00157053
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Nov 22, 2001
Primary completion
Aug 3, 2004
Completion
Aug 3, 2004
Last update
Aug 24, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Antihemophilic factor, human recombinant · F8 protein, human

Start the discussion